on-interventional study of Allergy immunotherapy in adult patients with House dust mite allergy
- Conditions
- House dust mite allergyJ30.3J45Other allergic rhinitisAsthma
- Registration Number
- DRKS00009983
- Lead Sponsor
- ALK-Abelló Arzneimittel GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 1525
Inclusion Criteria
Clinical history and a positive test of house dust mite sensitisation (skin prick test and/or specific IgE) with at least one of the following conditions:
? Persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication.
? House dust mite allergic asthma not well controlled by inhaled corticosteroids and associated with mild to severe house dust mite allergic rhinitis; age: 18-65 years; no contraindication to a prescription of ACARIZAX®
Exclusion Criteria
Contraindications according to ACARIZAX SmPC
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method